220
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Uterine perivascular epithelioid cell tumour

, &
 

Abstract

Uterine perivascular epithelioid cell tumour (PEComa) is a rare disease and its biological behaviour remains unclear. This paper describes the clinical, histological and immunohistochemical features of three cases of uterine PEComa to add to our limited knowledge of the biological characteristics of these tumours. Histologically, the tumours were characterised by an epithelioid arrangement of tumour cells with abundant clear to eosinophilic, pale, granular cytoplasm. Immunohistochemically, the tumours were uniformly positive for HMB45, desmin and progesterone receptor; they were uniformly negative for h-caldesmon, α-smooth muscle actin, CD34, epithelial membrane antigen (EMA) and oestrogen receptor (ER). Review of the literature suggests that the size of the primary tumour (> 5 cm in diameter) and high mitotic rates are two important indicators of recurrence. Treatment options are limited though new mTOR inhibitors show some promise in early reports.

Acknowledgement

The authors would like to express their deep thanks to CaiYun Zhou for her kind help in the pathological and immunohistochemical work.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.